First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease.
BACKGROUND: Patients with chronic kidney disease are at increased risk for cardiovascular disease, but the efficacy and safety of simvastatin and aspirin are unknown in this patient group. METHODS: Patients were randomly assigned in a 2 x 2 factorial design to the administration of: (1) 20 mg of sim...
Main Authors: | Baigent, C, Landray, M, Leaper, C, Altmann, P, Armitage, J, Baxter, A, Cairns, H, Collins, R, Foley, R, Frighi, V, Kourellias, K, Ratcliffe, P, Rogerson, M, Scoble, J, Tomson, C, Warwick, G, Wheeler, D |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2005
|
Similar Items
-
The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD.
by: Landray, M, et al.
Published: (2006) -
Biochemical safety and efficacy of co-administration of Ezetimibe and simvastatin among patients with chronic kidney disease: The second UK-Heart and renal protection (UK-HARP-II) study
by: Landray, M, et al.
Published: (2003) -
Efficacy and safety of simvastatin and safety of low-dose aspirin among patients with chronic kidney disease: Final results of the first UK-Heart and Renal Protection (UK-HARP-1) study.
by: Baigent, C, et al.
Published: (2002) -
Safety of long-term simvastatin discontinuation Reply
by: Bulbulia, R, et al.
Published: (2012) -
Misrepresentation of statin safety evidence.
by: Armitage, J, et al.
Published: (2014)